DK1318828T3 - Oralt administrerede peptider til bedring af aterosklerose - Google Patents

Oralt administrerede peptider til bedring af aterosklerose

Info

Publication number
DK1318828T3
DK1318828T3 DK01966198.2T DK01966198T DK1318828T3 DK 1318828 T3 DK1318828 T3 DK 1318828T3 DK 01966198 T DK01966198 T DK 01966198T DK 1318828 T3 DK1318828 T3 DK 1318828T3
Authority
DK
Denmark
Prior art keywords
orally administered
peptides
administered peptides
atherosclerosis
improve atherosclerosis
Prior art date
Application number
DK01966198.2T
Other languages
Danish (da)
English (en)
Inventor
Alan M Fogelman
Gattadahalli M Anantharamaiah
Mohamad Navab
Original Assignee
Univ California
Uab Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Uab Research Foundation filed Critical Univ California
Application granted granted Critical
Publication of DK1318828T3 publication Critical patent/DK1318828T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurosurgery (AREA)
DK01966198.2T 2000-08-24 2001-08-23 Oralt administrerede peptider til bedring af aterosklerose DK1318828T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/645,454 US6664230B1 (en) 2000-08-24 2000-08-24 Orally administered peptides to ameliorate atherosclerosis
PCT/US2001/026497 WO2002015923A1 (en) 2000-08-24 2001-08-23 Orally administered peptides to ameliorate atherosclerosis

Publications (1)

Publication Number Publication Date
DK1318828T3 true DK1318828T3 (da) 2010-08-09

Family

ID=24589089

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01966198.2T DK1318828T3 (da) 2000-08-24 2001-08-23 Oralt administrerede peptider til bedring af aterosklerose

Country Status (15)

Country Link
US (2) US6664230B1 (cg-RX-API-DMAC10.html)
EP (3) EP1318828B1 (cg-RX-API-DMAC10.html)
JP (6) JP3822167B2 (cg-RX-API-DMAC10.html)
CN (6) CN1224419C (cg-RX-API-DMAC10.html)
AT (2) ATE464060T1 (cg-RX-API-DMAC10.html)
AU (4) AU8673201A (cg-RX-API-DMAC10.html)
CA (3) CA2420222C (cg-RX-API-DMAC10.html)
CY (1) CY1110204T1 (cg-RX-API-DMAC10.html)
DE (2) DE60144543D1 (cg-RX-API-DMAC10.html)
DK (1) DK1318828T3 (cg-RX-API-DMAC10.html)
EA (2) EA006488B1 (cg-RX-API-DMAC10.html)
ES (2) ES2438779T3 (cg-RX-API-DMAC10.html)
IL (3) IL154545A0 (cg-RX-API-DMAC10.html)
PT (1) PT1318828E (cg-RX-API-DMAC10.html)
WO (1) WO2002015923A1 (cg-RX-API-DMAC10.html)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7199102B2 (en) * 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US8568766B2 (en) * 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US7166578B2 (en) * 2000-08-24 2007-01-23 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7144862B2 (en) * 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7723303B2 (en) 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US6930085B2 (en) 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
DE10222234A1 (de) * 2002-05-16 2003-11-27 Roche Diagnostics Gmbh Kontroll- und Kalibrationsmaterial für Blutgerinnungstests
US20090011974A1 (en) * 2002-10-30 2009-01-08 Bocharov Alexander V Scavenger Receptor B1 (Cla-1) Targeting for the Treatment of Infection, Sepsis and Inflammation
EP3254673A1 (en) * 2002-11-13 2017-12-13 The UAB Research Foundation Synthetic single domain polypeptides mimicking apolipoprotein e and methods of use
WO2004094471A2 (en) * 2003-04-22 2004-11-04 Avanir Pharmaceuticals Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia
US20050159362A1 (en) * 2003-04-22 2005-07-21 Sircar Jagadish C. Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia
GB0311081D0 (en) * 2003-05-14 2003-06-18 Btg Internat Limted Treatment of neurodegenerative conditions
EP2324828A1 (en) * 2003-08-18 2011-05-25 BTG International Limited Treatment for neurodegenerative conditions
AU2004296829A1 (en) 2003-12-05 2005-06-23 The Cleveland Clinic Foundation Risk markers for cardiovascular disease
GB0329958D0 (en) 2003-12-24 2004-01-28 Univ Manchester Treatment of viral infections
GB0404374D0 (en) 2004-02-27 2004-03-31 Univ Manchester Treatment of bacterial infections
SI1735349T1 (sl) * 2004-04-15 2010-12-31 Athera Biotechnologies Ab Postopek ocenitve tveganja ishemske kardiovaskularne bolezni z uporabo fosforilholinskih konjugatov
WO2005118166A2 (en) 2004-06-04 2005-12-15 Teva Pharmaceutical Industries, Ltd. Pharmaceutical composition containing irbesartan
EP1753782A1 (en) * 2004-06-09 2007-02-21 Avanir Pharmaceuticals Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia
MXJL06000069A (es) * 2004-06-09 2007-04-10 Avanir Pharmaceuticals Derivados heterociclicos para el tratamiento de hiperlipidemia y enfermedades relacionadas.
KR20070043711A (ko) * 2004-06-09 2007-04-25 아바니르 파마슈티컬스 고콜레스테롤혈증과 관련 질환의 치료를 위한 소분자
JP5048486B2 (ja) 2004-07-16 2012-10-17 トラスティーズ オブ タフツ カレッジ アポリポタンパク質a1の模倣物とその使用
US20060173067A1 (en) * 2004-08-11 2006-08-03 The Regents Of The University Of California Small molecules for the treatment of atherosclerosis
US7378396B2 (en) * 2004-08-11 2008-05-27 The Cleveland Clinic Foundation Therapeutic agents and methods for cardiovascular disease
US20060205669A1 (en) * 2004-09-16 2006-09-14 The Regents Of The University Of California G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
WO2006053754A1 (en) * 2004-11-19 2006-05-26 Novartis Ag COMBINATIONS OF ANTI-ATHEROSCLEROTIC PEPTIDES AND AN mTOR INHIBITING AGENT AND THEIR METHODS OF USE
GB0425932D0 (en) * 2004-11-25 2004-12-29 Btg Int Ltd Structured phospholipids
KR20070089996A (ko) * 2004-12-06 2007-09-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 세동맥의 구조 및 기능의 개선 방법
GB0504333D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Treatment of cytokine dysregulation
GB0504362D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Cytokine modulators
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
AU2006242651B2 (en) * 2005-04-29 2013-05-16 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
GR1005428B (el) * 2005-05-27 2007-02-01 Χαραλαμπος Αλεξοπουλος Συνθετικα λιποπεπτιδια με αντιαθηρογονο δραση, που εμποδιζουν την οξειδωση της λιποπρωτεϊνης χαμηλης πυκνοτητας (ldl) και αναστελλουν την απενεργοποιηση του ενζυμου της paf ακετυλοϋδρολασης (paf-ah)
GB0513096D0 (en) * 2005-06-28 2005-08-03 Strathclyde Treatment of microbial infections
WO2007055873A2 (en) * 2005-11-04 2007-05-18 Avanir Pharmaceuticals Process for the manufacture of peptide facilitators of reverse cholesterol transport
US8440695B2 (en) * 2005-11-09 2013-05-14 St Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
ES2402823T3 (es) * 2006-06-01 2013-05-09 Institut De Cardiologie De Montreal Compuesto para uso en el tratamiento de estenosis valvular
WO2007149355A2 (en) * 2006-06-16 2007-12-27 Lipid Sciences, Inc. Novel peptides that promote lipid efflux
US20080227686A1 (en) * 2006-06-16 2008-09-18 Lipid Sciences, Inc. Novel Peptides that Promote Lipid Efflux
US20080206142A1 (en) * 2006-06-16 2008-08-28 Lipid Sciences, Inc. Novel Peptides That Promote Lipid Efflux
EP2049137A4 (en) * 2006-08-08 2013-05-01 Univ California SALICYLANILIDES AS AMPLIFIERS OF THE ORAL RELEASE OF THERAPEUTIC PEPTIDES
US20080138284A1 (en) * 2006-09-26 2008-06-12 Lipid Sciences, Inc. Novel Peptides That Promote Lipid Efflux
ATE533783T1 (de) * 2006-12-13 2011-12-15 Univ California Potente und selektive mittlersubstanzen von cholesterolefflux
US20080268038A1 (en) * 2007-04-26 2008-10-30 Wolfe Robert R Compositions and Approaches for Increasing Diet Induced Thermogenesis, Inducing Weight Loss and Maintaining Muscle Mass and Strength
CN101730548A (zh) * 2007-07-09 2010-06-09 诺瓦提斯公司 保存二级肽结构
JP2010538005A (ja) 2007-08-28 2010-12-09 ユーエービー リサーチ ファウンデーション 合成アポリポ蛋白質e模倣ポリペプチドおよび使用方法
AU2008296487A1 (en) 2007-08-28 2009-03-12 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
PT2193142E (pt) * 2007-08-30 2015-04-22 Curedm Group Holdings Llc Composições e procedimentos de utilização de peptídeos pro-ilhota e seus análogos
AU2008335717A1 (en) * 2007-12-11 2009-06-18 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
US20110020242A1 (en) * 2007-12-12 2011-01-27 Gang Zheng High-density lipoprotein-like peptide-phospholipid scaffold ("hpps") nanoparticles
EP2324048A2 (en) * 2008-07-30 2011-05-25 Cosmix Therapeutics Llc Peptide therapeutics that bind vegf and methods of use thereof
ITTO20080894A1 (it) * 2008-12-02 2010-06-03 Bioindustry Park Del Canavese S P A Uso dell'aptoglobina, peptidi leganti l'aptoglobina, polimeri contenenti gli stessi e loro uso
MX2011008599A (es) 2009-02-16 2011-11-18 Cerenis Therapeutics Sa Peptidos mimeticos de la apolipoproteina a-i.
CN102753576A (zh) * 2009-09-30 2012-10-24 首尔大学教产学协力团 载脂蛋白a-1模拟肽以及包含其的用于治疗高血脂及高血脂相关疾病的治疗剂
WO2011044545A2 (en) 2009-10-09 2011-04-14 Sigalov Alexander B Methods and compositions for targeted imaging
US12419839B2 (en) 2009-10-09 2025-09-23 Signablok, Inc. Methods and compositions for targeted delivery of protein fragments
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
ES2455124T5 (es) 2010-05-05 2018-05-08 Zora Biosciences Oy Biomarcadores lipidómicos para la aterosclerosis y afección cardíaca
CN103154742B (zh) * 2010-06-20 2017-11-21 佐拉生物科学公司 用于鉴定高风险冠状动脉疾病患者的脂质组学标志
LT2673296T (lt) 2011-02-07 2019-02-25 Cerenis Therapeutics Holding Sa Lipoproteino kompleksai ir jų gamyba ir jų panaudojimai
WO2012108990A2 (en) * 2011-02-07 2012-08-16 Indiana University Research And Technology Corporation Peptide-phospholipid conjugates
US9539300B2 (en) 2012-03-31 2017-01-10 The Regents Of The University Of California Modulating disease through genetic engineering of plants
US10087234B2 (en) 2012-11-06 2018-10-02 Les Hopitaux Universitaires De Geneve Mimetic peptides
ES2753381T3 (es) 2013-03-14 2020-04-08 Uab Research Foundation Miméticos de apolipoproteína y usos de los mismos
US10017551B2 (en) 2013-03-15 2018-07-10 The Regents Of The University Of California Peptides having reduced toxicity that stimulate cholesterol efflux
US9850278B2 (en) 2013-04-25 2017-12-26 Carmel-Haifa University Economic Corp. Synthetic anti-inflammatory peptides and use thereof
EP2853259A1 (en) 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Reconstituted high density lipoproteins composition and uses thereof
RU2016144908A (ru) 2014-05-02 2018-06-05 Серени Терапеутикс Холдинг Са Маркеры hdl-терапии
JP7081923B2 (ja) 2014-07-31 2022-06-07 ユーエイビー リサーチ ファンデーション アポe模倣ペプチド及び血漿コレステロールを取り除くためのより高い効果
US10532105B2 (en) 2015-07-10 2020-01-14 Peptinovo Biopharma, LLC. Formulations for improving the efficacy of hydrophobic drugs
CN105061579B (zh) * 2015-08-18 2018-08-28 北京大学人民医院 脂多糖结合蛋白在制备类风湿关节炎相关药物中的应用
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
EP3490579B1 (en) 2016-07-27 2025-09-10 Hartis-Pharma SA Therapeutic combinations to treat red blood cell disorders
WO2018063796A1 (en) 2016-09-28 2018-04-05 The Regents Of The University Of California Ezetimibe-associated apoa-1 mimetic peptides showing enhanced synergism
US10426817B2 (en) 2017-01-24 2019-10-01 Macregen, Inc. Treatment of age-related macular degeneration and other eye diseases with apolipoprotein mimetics
IT201800009384A1 (it) * 2018-10-11 2020-04-11 Cosmo Srl Peptide for cosmetic application
KR20230004605A (ko) 2020-04-16 2023-01-06 아비오닉스 파마 에스에이 지질 결합 단백질-기반 복합체를 사용하여 급성 상태를 치료하는 방법
CA3197168A1 (en) 2020-10-01 2022-04-07 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
RU2760498C1 (ru) * 2021-02-09 2021-11-25 Вахтанг Владимирович Гобеджишвили Способ прогнозирования развития избыточного рубцеобразования у больных после проктологической операции
CA3216226A1 (en) 2021-04-15 2022-10-20 Abionyx Pharma Sa Use of lipid binding protein-based complexes in organ preservation solutions
WO2023168350A2 (en) * 2022-03-03 2023-09-07 University Of Maryland, Baltimore Synthetic amphipathic helical peptides and treatment methods using synthetic amphipathic helical peptides
CN119317440A (zh) 2022-04-06 2025-01-14 阿比奥尼克斯制药公司 使用基于脂质结合蛋白的复合物治疗白细胞增多、内皮功能障碍和心脏炎的方法
US20250230208A1 (en) 2022-04-06 2025-07-17 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
CA3258787A1 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa METHODS OF TREATMENT OF HYPERINFLAMMATORY DISEASES USING LIPID-BINDING PROTEIN COMPLEXES
WO2023237935A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein-based complexes
KR20260010675A (ko) 2023-01-13 2026-01-21 아비오닉스 파마 에스에이 지질 결합 단백질 분자 치료
IL327995A (en) 2023-10-31 2026-06-01 Abionyx Pharma Sa Lipid binding protein molecule therapy
WO2025147594A1 (en) * 2024-01-04 2025-07-10 University Of Florida Research Foundation, Incorporated Peptides and method of use in preparing nanodiscs

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3767040A (en) 1971-03-01 1973-10-23 Minnesota Mining & Mfg Pressure-sensitive polyurethane adhesives
US4155913A (en) 1973-02-08 1979-05-22 Hoffmann-La Roche Inc. Thienotriazolodiazepine derivatives
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
US4643988A (en) 1984-05-15 1987-02-17 Research Corporation Amphipathic peptides
US5182261A (en) * 1989-07-13 1993-01-26 The Rockefeller University Modified transforming growth factor alpha oligopeptides and pharmaceutical compositions thereof
AU662885B2 (en) 1990-06-07 1995-09-21 Scripps Research Institute, The APO AI polypeptides, antibodies, and immunoassays
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
US5646119A (en) * 1991-11-01 1997-07-08 Periodontix, Inc. D-amino acid histatin-based peptides as anti-fungal and anti-bacterial agents
SE9103701D0 (sv) * 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
EP0644897B1 (en) 1992-06-12 1998-09-16 N.V. Innogenetics S.A. New peptides and proteins, process for their preparation and their use as cholesterol acceptors
US5344822A (en) 1992-08-12 1994-09-06 The Rogosin Institute Methods useful in endotoxin prophylaxis and therapy
US5733549A (en) 1992-08-14 1998-03-31 Shino-Test Corporation Peptides including amino acid sequences selected from lipoprotein (a) and apolipoprotein (a), antibodies recognizing these amino acid sequences, and methods of determination using these antibodies
US5721138A (en) 1992-12-15 1998-02-24 Sandford University Apolipoprotein(A) promoter and regulatory sequence constructs and methods of use
CN1135181A (zh) * 1993-09-14 1996-11-06 Cytel有限公司 使用泛dr结合肽改变免疫应答
US6169073B1 (en) * 1995-02-16 2001-01-02 Bayer Corporation Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function
CN1101680C (zh) 1995-09-09 2003-02-19 弗·哈夫曼-拉罗切有限公司 噻吩并三唑并二氮杂䓬增加载脂蛋白a-1含量的用途
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
JP2000509020A (ja) * 1996-03-29 2000-07-18 ダリオ・ボッフェリ コレステロールおよび他の脂質の取り込みを阻害する両親媒性分子
US6200955B1 (en) * 1996-06-11 2001-03-13 Commonwealth Biotechnologies, Inc. Heparin binding peptides
US6156727A (en) * 1996-09-05 2000-12-05 Uab Research Foundation Anti-atherosclerotic peptides and a transgenic mouse model of antherosclerosis
US6696545B1 (en) * 1997-04-11 2004-02-24 Sangstat Medical Corporation Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation
IN185761B (cg-RX-API-DMAC10.html) 1997-05-13 2001-04-28 Council Scient Ind Res
US6037323A (en) * 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6518412B1 (en) 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6046166A (en) 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6287590B1 (en) 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
WO1999047566A1 (en) 1998-03-17 1999-09-23 The Uab Research Foundation Synthetic peptides that enhance ldl uptake
KR20010099605A (ko) * 1998-07-30 2001-11-09 존 프랫 Hiv 막융합 억제제
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis

Also Published As

Publication number Publication date
JP2004506693A (ja) 2004-03-04
CA2718348C (en) 2012-07-17
CN1943781B (zh) 2011-01-12
CN1931359B (zh) 2014-10-15
US6933279B2 (en) 2005-08-23
CN100579984C (zh) 2010-01-13
JP3822167B2 (ja) 2006-09-13
EA200300289A1 (ru) 2003-08-28
CN1911439A (zh) 2007-02-14
CA2420222C (en) 2009-03-03
AU2009202705C1 (en) 2013-10-17
EA006488B1 (ru) 2005-12-29
ES2342258T3 (es) 2010-07-05
PT1318828E (pt) 2010-06-11
JP2008150358A (ja) 2008-07-03
EP2198877A3 (en) 2010-12-01
JP2006056899A (ja) 2006-03-02
US6664230B1 (en) 2003-12-16
CY1110204T1 (el) 2015-01-14
CN1469754A (zh) 2004-01-21
CN1224419C (zh) 2005-10-26
CN1931358A (zh) 2007-03-21
HK1110011A1 (en) 2008-07-04
ATE506958T1 (de) 2011-05-15
EP1318828A4 (en) 2005-04-27
JP4364222B2 (ja) 2009-11-11
AU2006200035A1 (en) 2006-02-02
CA2718348A1 (en) 2002-02-28
CN1739787A (zh) 2006-03-01
IL154545A0 (en) 2003-09-17
CA2639651A1 (en) 2002-02-28
DE60141842D1 (de) 2010-05-27
IL154545A (en) 2011-10-31
EA009528B1 (ru) 2008-02-28
JP2006312650A (ja) 2006-11-16
ATE464060T1 (de) 2010-04-15
CA2420222A1 (en) 2002-02-28
CN1931359A (zh) 2007-03-21
JP5241790B2 (ja) 2013-07-17
EP2198877A2 (en) 2010-06-23
AU8673201A (en) 2002-03-04
JP2010280718A (ja) 2010-12-16
JP2007277250A (ja) 2007-10-25
EP2198877B1 (en) 2013-10-16
US20030045460A1 (en) 2003-03-06
ES2438779T3 (es) 2014-01-20
EP1318828A1 (en) 2003-06-18
AU2009202705A1 (en) 2009-07-23
EA200501744A1 (ru) 2006-06-30
AU2001286732B2 (en) 2005-10-06
WO2002015923A1 (en) 2002-02-28
HK1055400A1 (en) 2004-01-09
IL206114A (en) 2014-05-28
EP1864675A1 (en) 2007-12-12
JP4205713B2 (ja) 2009-01-07
CA2639651C (en) 2011-02-08
AU2006200035B2 (en) 2007-09-13
DE60144543D1 (de) 2011-06-09
AU2009202705B2 (en) 2013-01-10
CN1943781A (zh) 2007-04-11
EP1864675B1 (en) 2011-04-27
EP1318828B1 (en) 2010-04-14

Similar Documents

Publication Publication Date Title
DE60141842D1 (de) Erosklerose
ATE516811T1 (de) Peptide vom g-typ zur linderung von atherosklerose
BR9902086A (pt) Formulações farmacêuticas.
FR14C0080I2 (fr) Methode d'administration d'un anticorps
DE69928270D1 (de) Neutraler aminosäurentransporter und korrespondierendes gen
DK1539063T3 (da) Leveringssystem og fremgangsmåde til fremstilling af et leveringssystem
DE69822172D1 (de) Levosimendanhaltige oral anzuwendende arzneizusammensetzungen
FR2833333B1 (fr) Joint d'etancheite metallique en s peu profond
BR0205983A (pt) fármacos peptìdicos antiangiogênicos
WO2006034056A3 (en) G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
NO20073914L (no) Biologisk aktive peptider
DK0966299T3 (da) Hidtil ukendte orale formuleringer af calcitonin.
EP1311239A4 (en) ORAL ADMINISTRATION OF PEPTIDES
EP1435693A4 (en) GAIN CIRCUIT
BR9714376A (pt) Antagonistas de somatostatina
FR2836153B1 (fr) Tensioactif a base d'acide amine et composition cosmetique l'utilisant
DE50107267D1 (de) "Klappenbetätigungsvorrichtung"
FR2821025B1 (fr) Brides d'echappement minces
IT1318654B1 (it) Composizioni farmaceutiche comprendenti agenti antiinfiammatori e lorousi.
KR970000226A (ko) S-이부프로펜의 경구용 제형
FR2820425B1 (fr) Melange de peptides issus d'une proteine nef et leurs applications
ITTS20010001U1 (it) Puzzle avente un'immagine su entrambe le superfici
IT249451Y1 (it) Struttura di snodo particolarmente per l'orientazione di telecamere e/o custodie contenenti telecamere.
NO20052957L (no) Chorionisk somatomammotropin hormon spleisevarianter
FR2805886B3 (fr) Projecteur d'illumination exterieure ciblee